Dr Reddy's Laboratories reported resilient operating performance for FY26 with record annual revenues, despite a sales stock adjustment related to Lenalidomide impacting revenues by ₹453 crore and additional provisions and impairments totaling over ₹300 crore. The company faced one-time impacts including a VAT liability provision of ₹114 crore and impairments of ₹135 crore for CAR T therapy programs and ₹93 crore for a partner product trial. Excluding these adjustments, the adjusted revenue for the quarter was ₹7,969 crore, showing a year-over-year decline of 6%, primarily due to lower Lenalidomide sales.

Financial Performance

The gross margin was affected by price erosion in unbranded generics, standing at 48% for the quarter and 53.5% for the year on an adjusted basis. The company expects margins to improve over 50% in FY27 with ongoing cost efficiencies. Strategic progress included regulatory approval of Semaglutide in Canada and India, and the US FDA acceptance of a biosimilar candidate for review. The company launched 25 new products in North America and 49 in emerging markets during the quarter.

Key Financial Metrics

The underlying base business excluding Lenalidomide delivered double-digit growth. North America Generic Business reported revenue of $199 million for the quarter and $1.3 billion for FY26, while emerging markets reported revenue of ₹1,806 crore in Q4FY26, a growth of 29% year over year. The India business posted revenue of ₹1,566 crore in Q4FY26, delivering a year-over-year growth of 20%.

Strategic Outlook

Dr Reddy's remains focused on strengthening its core business while driving future growth in biosimilars, peptides, and consumer health. Management is optimistic about maintaining growth momentum in its base business and achieving a 24-25% effective tax rate for FY27. The Board recommended payment of a dividend of ₹8 per equity share of face value ₹1 each, equivalent to 800% of the face value for the year ended March 31, 2026, subject to shareholder approval.

Dr. Reddy's Laboratories has announced that it will consider its financial results for the first quarter (Q1) on July 22. The announcement signals an upcoming disclosure that is expected to draw significant attention from investors and market participants tracking the pharmaceutical sector.

Key Announcement Details

The following table summarizes the key details of the announcement:

What to Watch

The board meeting scheduled for July 22 will focus on reviewing and considering the Q1 financial results of Dr. Reddy's Laboratories. Stakeholders and analysts are expected to closely monitor the outcome of this meeting for insights into the company's quarterly financial performance.